Holly Henderson
Family · Golden, ILNPI 1710034954
Payments from drug & device makers
Across 177 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$795
- AstraZeneca$505
- Otsuka America Pharmaceutical, Inc.$372
- Novo Nordisk$316
- Novartis$249
- Medtronic$221
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,619100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 50 | $795 |
| AstraZeneca | 22 | $505 |
| Otsuka America Pharmaceutical, Inc. | 14 | $372 |
| Novo Nordisk | 20 | $316 |
| Novartis | 14 | $249 |
| Medtronic | 3 | $221 |
| Axsome Therapeutics, Inc. | 6 | $165 |
| Amgen | 7 | $123 |
| Gilead | 3 | $104 |
| Lilly USA, LLC | 5 | $84 |
| Teva Pharmaceuticals USA, Inc. | 3 | $77 |
| Edwards Lifesciences | 1 | $77 |
| Boehringer Ingelheim | 4 | $73 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $60 |
| Lundbeck LLC | 3 | $56 |
| Johnson & Johnson | 3 | $54 |
| Exact Sciences | 2 | $41 |
| Pfizer | 2 | $32 |
| Xeris Pharmaceuticals, Inc. | 2 | $31 |
| Corium, LLC | 1 | $30 |
| Sumitomo Pharma America, Inc. | 2 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Bayer | 1 | $21 |
| Bard Access Systems, Inc. | 1 | $19 |
| Vertex | 1 | $19 |
| Harmony Biosciences LLC | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,619 in reported general payments places this provider in the 90th percentile of 4,941 family providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 41 | $42,562 |
| OzempicSemaglutide | 33 | $42,028 |
| JardianceEmpagliflozin | 30 | $30,042 |
| EliquisApixaban | 31 | $26,658 |
| FarxigaDapagliflozin Propanediol | 21 | $15,835 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 29 | $14,500 |
| JanuviaSitagliptin Phosphate | 12 | $10,180 |
| XareltoRivaroxaban | 11 | $8,422 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $7,395 |
| MotegrityPrucalopride Succinate | 12 | $6,739 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,814 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $4,865 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $3,863 |
| Celecoxib | 16 | $1,523 |
| Humulin 70-30Insulin Nph Hum/Reg Insulin Hm | 13 | $1,480 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $73 | $44,54259 claims |
| Lilly USA, LLCMounjaro, Humulin 70-30 | $84 | $44,04254 claims |
| Novo NordiskOzempic | $316 | $42,02833 claims |
| PfizerEliquis | $32 | $26,65831 claims |
| AstraZenecaFarxiga, Symbicort | $505 | $20,70035 claims |
| Johnson & JohnsonXarelto | $54 | $8,42211 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $15 | $6,73912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,941 family providers in Illinois.
Other family in Golden
- Ruth CarricoChicago$582K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Brooke KennardBloomington$208K
- Amy BrownellElk Grove Village$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.